Kacy Rogers, NP
Nurse Practitioner · Indianapolis, INNPI 1164913703
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,950 of the $76,633 with a category attached, or 71.7%. Amgen accounts for 82.2% of it on its own, with 28 other manufacturers making up the rest. 2025 is the largest year on record at $34,110, more than ten times the $888 reported in 2021. Among nurse practitioner clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 468 payments — averaging $163.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$63K
- AstraZeneca$8K
- Kyowa Kirin, Inc.$3K
- Radius Health, Inc.$1K
- Boston Scientific$294
- Vertos Medical, Inc.$201
- plus $1K from 23 others
What the payments were for
- Consulting fees$2,0403%
- Speaking & faculty fees$54,95072%
- Travel & lodging$10,61914%
- Food & beverage$8,96612%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 263 | $63,000 |
| AstraZeneca | 40 | $7,554 |
| Kyowa Kirin, Inc. | 15 | $3,314 |
| Radius Health, Inc. | 85 | $1,262 |
| Boston Scientific | 11 | $294 |
| Vertos Medical, Inc. | 1 | $201 |
| Arbor Pharmaceuticals, Inc. | 14 | $160 |
| Abbott | 1 | $148 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $109 |
| Lundbeck LLC | 4 | $77 |
| AbbVie | 4 | $76 |
| Biomarin Pharmaceutical Inc. | 1 | $68 |
| IBSA Pharma Inc. | 3 | $54 |
| Alkermes, Inc. | 3 | $53 |
| Bioventus LLC | 1 | $29 |
| Novo Nordisk | 2 | $29 |
| Johnson & Johnson | 2 | $25 |
| Relievant Medsystems, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Si-bone, Inc. | 1 | $19 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Smith+Nephew | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| GRT US Holding, Inc. | 1 | $13 |
| Indivior Inc. | 1 | $12 |
| Medtronic | 1 | $11 |
| MML US, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$58,908
- CRYSVITA$3,021
- Strensiq$1,615
- Prolia$698
- mild Device Kit$201
- Proclaim IPG$148
- Tymlos$146
- Superion Indirect Decompression System$138
How this compares
$76,633 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 91 | $391,589 |
| TymlosAbaloparatide | 129 | $357,014 |
| Teriparatide | 89 | $229,221 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 12 | $29,932 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 13 | $728 |
| Droplet Pen NeedlePen Needle, Diabetic | 19 | $595 |
| Alendronate Sodium | 57 | $389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo | $16 | $391,58991 claims |
| Radius Health, Inc.Tymlos | $1,262 | $357,014129 claims |
| AmgenEvenity (2 Syringes) | $63,000 | $29,93212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.
Other nurse practitioner in Indianapolis
- Kristi OrbaughIndianapolis$1.3M
- Brittany SavageIndianapolis$51K
- Jennifer MaahsIndianapolis$36K
- Dawn SteppIndianapolis$31K
- Angela PierceIndianapolis$19K
- Donna DoerfflerIndianapolis$13K
- Shannon ColterIndianapolis$12K
- Ellen RovnerIndianapolis$11K
- Kimberly EadsPlainfield$302K
- Sean GoddardFort Wayne$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.